Cooperative Agreement U01CA294757
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$512K
Federal Agency
National Cancer Institute
Awardee
Baylor University (C6T9BYG5EYX5)
Federal Grant Program
93.393
Assistance Type
Cooperative Agreement
Place of Performance
Waco, TX 76798, USA
Similar Awards
The National Cancer Institute (NCI) awarded a 5-year, $629,068 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to Albert Einstein College of Medicine to conduct an implementation study of integrated human papillomavirus (HPV) self-sampling in HIV care centers in Ethiopia. The study aims to leverage the Project ECHO (Extension for Community Healthcare Outcomes) virtual learning platform to promote experience sharing and technical assistance across 5 hospitals to improve...
This $643,363 Cooperative Agreement, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), will support a hybrid type III effectiveness-implementation trial to test best practices for deploying a "screen and treat" approach to cervical cancer screening using self-collected HPV DNA testing within HIV care and treatment facilities in Mozambique. The primary outcome is to increase the number of women screened and treated for...
This $753,446 Project Grant award from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) aims to adapt and test an intervention to improve cervical cancer screening and follow-up in three diverse, underserved populations: urban inner city Blacks/Haitians in Boston, Hispanic immigrants in Florida, and Hawaiian Natives/Pacific Islanders in Hawaii. The intervention combines education and quality improvement methods using a mechanism called Performance...
The Cooperative Agreement awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $1,245,116 to Emory University from September 1, 2024 to August 31, 2029. The project, "Enhancing Cervical Cancer Screening and Treatment in Women Living with HIV in Kenya (ENHANCE Linkage)", aims to adapt and test implementation strategies to expand HIV care to screen for and treat early precancerous cervical cancer lesions in a...
The National Cancer Institute (NCI) awarded a 5-year, $706,365 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to The Trustees of Columbia University in the City of New York to implement the WHO-endorsed "screen, triage, and treat" (ISTAR) approach for cervical cancer screening among women living with HIV in La Romana, Dominican Republic. The project aims to sustain implementation of the ISTAR approach and generate new data to inform effective and equitable...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $1,837,497 to New York University to conduct the KUPEWA project. The project aims to (A) identify optimal implementation strategies for increasing clinician recommendation of HPV vaccination for girls and young women aged 9-24 living with HIV in Malawi, (B) refine these strategies based on implementability, and (C) identify strategies that are effective,...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the federal grant program "Cancer Detection and Diagnosis Research" (CFDA 93.394), aims to develop a point-of-care HPV DNA test for cervical cancer screening in Mozambique. The total award is $585,943, with a performance period from September 1, 2024 to August 31, 2029. The key objectives are to: 1) Adapt existing extraction-free, multiplexed, isothermal nucleic acid amplification assays to detect 8...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program, aims to optimize a bundled breast and cervical cancer screening program in Cameroon. The $192,780 award to the University of Alabama at Birmingham (UAB) supports implementation science research to 1) evaluate the reach and effectiveness of the screening program across stationary and mobile clinics, 2) identify implementation outcomes of acceptability, appropriateness,...
This federal Project Grant award, totaling $477,869.00, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant aims to develop tailored, multilevel cervical cancer interventions for ethnically diverse Black women, including African American women and Black African immigrant women. The key objectives are to: 1) identify multilevel determinants of routine cervical cancer screening and follow-up adherence among these populations,...
The National Cancer Institute (NCI) awarded a $233,411 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to Pennsylvania State University's Milton S. Hershey Medical Center. The grant, titled "STORIES TO PREVENT (STOP) HPV CANCERS: A COMMUNICATION INTERVENTION TO INCREASE HPV VACCINATION AMONG DIVERSE POPULATIONS", aims to evaluate the impact of a narrative communication intervention delivered through digital and mobile technology on HPV vaccine...